{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:13:04Z","timestamp":1794636784695,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFFK0014"],"award-info":[{"award-number":["2024YFFK0014"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Multidrug resistance (MDR) is a major barrier to treat relapsed solid tumors. Carbon nanoparticles\u2011Fe(II) complex (CNSI-Fe) is composed of carbon nanoparticles and Fe\u00b2\u207a ions, which directly deliver Fe\n                      <jats:sup>2+<\/jats:sup>\n                      into tumor cells to induce ferroptosis. In this cohort analysis from a Phase I trial, we aim to evaluate the safety, imaging response, survival outcomes, and potential restoration of sensitivity to systemic therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nineteen patients in a Phase I study (NCT06048367) received the intratumoral injection of CNSI-Fe. The primary outcomes were safety and tolerability; secondary outcomes included radiographic response assessed by revised RECIST v1.1, tumor biology evaluated by necrosis and tumor growth rate (TGR), and long-term survival. All patients were followed after withdrawal from the study therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CNSI-Fe demonstrated an acceptable safety profile. CNSI-Fe consistently induced marked central necrosis on imaging despite minimal revised RECIST v1.1 shrinkage. Four patients (4\/19, 21.1%) with heavily pretreated, progressive disease (ovarian serous carcinoma, pancreatic adenocarcinoma, myoepithelioma-like tumor of the vulvar region, and thyroid carcinoma) achieved long-term survival for 28.9\u201336.2 months post CNSI-Fe injection, accompanied by restored response to chemotherapies or targeted agents to which they were previously resistant (e.g., resensitization-restored sensitivity, hypersensitization-enhanced sensitivity). These four patients (4\/19, 21.1%) demonstrated renewed sensitivity to subsequent systemic therapies (e.g., paclitaxel, carboplatin, bevacizumab, irinotecan liposome, and lenvatinib).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case series provides preliminary clinical evidence that CNSI-Fe could weaken MDR and resensitize solid tumors to systemic therapy. These findings warrant biomarker-integrated expansion cohorts and Phase II trials of CNSI-Fe-based combinations with radiotherapy, chemotherapy, targeted therapy, and immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The clinical data were derived from a completed prospective, single-arm, dose-escalation first-in-human trial (The Center for Drug Evaluation of the National Medical Products Administration, Registration No.: CTR20222235, Approval date: September 1, 2022; ClinicalTrials.gov Identifier: NCT06048367, First submitted date: August 24, 2023; RRID: SCR_002309).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16216-7","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:55:31Z","timestamp":1780671331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles\u2011Fe(II) complex trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Ping","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huashan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehui","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"16216_CR1","doi-asserted-by":"publisher","first-page":"101838","DOI":"10.1016\/j.xcrm.2024.101838","volume":"5","author":"M Shi","year":"2024","unstructured":"Shi M, Yang Y, Huang N, Zeng D, Mo Z, Wang J, et al. Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy. Cell Rep Med. 2024;5:101838.","journal-title":"Cell Rep Med"},{"key":"16216_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13046-024-03227-0","volume":"43","author":"O Novoplansky","year":"2024","unstructured":"Novoplansky O, Jagadeeshan S, Prasad M, Yegodayev KM, Marripati D, Abu Shareb R, et al. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer. J Exp Clin Cancer Res. 2024;43:308.","journal-title":"J Exp Clin Cancer Res"},{"key":"16216_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","volume":"22","author":"M Ge","year":"2025","unstructured":"Ge M, Chen X-Y, Huang P, Fleishman JS, Yang D-H, Wu Z-X, et al. Understanding and overcoming multidrug resistance in cancer. Nat Rev Clin Oncol. 2025;22:760\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"16216_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25:353\u201369.","journal-title":"Nat Rev Immunol"},{"key":"16216_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"16216_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","volume":"25","author":"A Wahida","year":"2025","unstructured":"Wahida A, Conrad M. Decoding ferroptosis for cancer therapy. Nat Rev Cancer. 2025;25:910\u201324.","journal-title":"Nat Rev Cancer"},{"key":"16216_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21:47.","journal-title":"Mol Cancer"},{"key":"16216_CR8","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.gendis.2025.101678","volume":"12","author":"L Wang","year":"2025","unstructured":"Wang L, Zhu Y, Huang C, Pan Q, Wang J, Li H, et al. Targeting ferroptosis in cancer stem cells: a novel strategy to improve cancer treatment. Genes Dis. 2025;12:101678.","journal-title":"Genes Dis"},{"key":"16216_CR9","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/cac2.70064","volume":"45","author":"J Hu","year":"2025","unstructured":"Hu J, Li Y, Lian B, Mao Y, Zhao L. Mechanism and role of regulated cell death in tumor immunity and immunotherapy. Cancer Commun (Lond). 2025;45:1456\u201395.","journal-title":"Cancer Commun (Lond)"},{"key":"16216_CR10","doi-asserted-by":"publisher","first-page":"e08608","DOI":"10.1002\/smll.202508608","volume":"21","author":"T Lu","year":"2025","unstructured":"Lu T, Wu W, Chen H, Zuo Q, Wu H, Zhao S, et al. Quaternary nanobomb triggered ferroptosis and pyroptosis enhance immunogenicity and immunotherapy of triple negative breast cancer. Small. 2025;21:e08608.","journal-title":"Small"},{"key":"16216_CR11","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.bioorg.2024.107331","volume":"146","author":"W Ma","year":"2024","unstructured":"Ma W, Hu N, Xu W, Zhao L, Tian C, Kamei KI. Ferroptosis inducers: a new frontier in cancer therapy. Bioorg Chem. 2024;146:107331.","journal-title":"Bioorg Chem"},{"issue":"47","key":"16216_CR12","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.1039\/D5NR03627E","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, Zhou Q, Fan Y, Liu TM, Zhu L, Liu M. Nanomaterial-mediated ferroptosis as a promising strategy for cancer therapy. Nanoscale. 2025;17(47):27066\u201384.","journal-title":"Nanoscale"},{"key":"16216_CR13","doi-asserted-by":"publisher","first-page":"114562","DOI":"10.1016\/j.colsurfb.2025.114562","volume":"250","author":"P Xie","year":"2025","unstructured":"Xie P, Qu T, Tang K, Huang Y, Zeng G, Yuan H, et al. Carbon nanoparticles-Fe(II) complex combined with sorafenib for ferroptosis-induced antitumor effects in triple-negative breast cancer. Colloids Surf B Biointerfaces. 2025;250:114562.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"16216_CR14","doi-asserted-by":"publisher","first-page":"19665","DOI":"10.1039\/D5RA03041B","volume":"15","author":"Y Huang","year":"2025","unstructured":"Huang Y, Tang K, Zeng G, Yuan H, Xin Q, Zhao Y, et al. Photothermal therapeutic effects and biosafety of a carbon nanoparticles-Fe(ii) complex for triple-negative breast cancer. RSC Adv. 2025;15:19665\u201375.","journal-title":"RSC Adv"},{"issue":"26","key":"16216_CR15","first-page":"29094","volume":"12","author":"P Xie","year":"2020","unstructured":"Xie P, Yang ST, Huang Y, Zeng C, Xin Q, Zeng G, et al. Carbon nanoparticles-Fe(II) complex for efficient tumor inhibition with low toxicity by amplifying oxidative stress. ACS Appl Mater Interfaces. 2020;12(26):29094\u2013102.","journal-title":"ACS Appl Mater Interfaces"},{"key":"16216_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12645-023-00196-5","volume":"14","author":"P Xie","year":"2023","unstructured":"Xie P, Huang Y, Tang K, Wu X, Zeng C, Yang ST, et al. Carbon nanoparticles-Fe(II) complex for efficient theranostics of xenografted colonic tumor. Cancer Nanotechnol. 2023;14:38.","journal-title":"Cancer Nanotechnol"},{"key":"16216_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","volume":"10","author":"EA Kuczynski","year":"2013","unstructured":"Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression\u2014implications for drug resistance. Nat Rev Clin Oncol. 2013;10:571\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"16216_CR18","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.esmoop.2022.100630","volume":"7","author":"L-N He","year":"2022","unstructured":"He L-N, Fu S, Ma H, Chen C, Zhang X, Li H, et al. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. ESMO Open. 2022;7:100630.","journal-title":"ESMO Open"},{"key":"16216_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41580-025-00843-2","volume":"26","author":"E Mishima","year":"2025","unstructured":"Mishima E, Nakamura T, Doll S, Proneth B, Fedorova M, Pratt DA, et al. Recommendations for robust and reproducible research on ferroptosis. Nat Rev Mol Cell Biol. 2025;26:615\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"16216_CR20","doi-asserted-by":"publisher","first-page":"175883592412661","DOI":"10.1177\/17588359241266188","volume":"16","author":"Q Zhong","year":"2024","unstructured":"Zhong Q, Zhang L, Wu L, Zhao J, Sun J, Fang Y, et al. Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1\/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis. Ther Adv Med Oncol. 2024;16:17588359241266188.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"16216_CR21","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1152\/ajpcell.00416.2025","volume":"330","author":"SA More","year":"2026","unstructured":"More SA, Ghosh A, Kulkarni OP, Mulay SR. Role of persistent necroinflammation in chronic tissue remodeling and organ fibrosis. Am J Physiol Cell Physiol. 2026;330(1):C40\u201355.","journal-title":"Am J Physiol Cell Physiol"},{"key":"16216_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1746-1596-8-119","volume":"8","author":"Q Xu","year":"2013","unstructured":"Xu Q, Cao Q, Liu N, Fang Z, Ye Z, Peng T. Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review. Diagn Pathol. 2013;8:119.","journal-title":"Diagn Pathol"},{"issue":"3","key":"16216_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/1754-9485.13847","volume":"69","author":"A Lasocki","year":"2025","unstructured":"Lasocki A, Sia J, Stuckey SL. Differentiation between radiation necrosis and true tumour progression after radiotherapy to intracranial metastases. J Med Imaging Radiat Oncol. 2025;69(3):414\u201324.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"4","key":"16216_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/cas.13510","volume":"109","author":"A Niida","year":"2018","unstructured":"Niida A, Nagayama S, Miyano S, Mimori K. Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling. Cancer Sci. 2018;109(4):884\u201392.","journal-title":"Cancer Sci"},{"issue":"6","key":"16216_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2214\/AJR.21.26538","volume":"218","author":"S Sheikhbahaei","year":"2022","unstructured":"Sheikhbahaei S, Marcus CV, Sadaghiani MS, Rowe SP, Pomper MG, Solnes LB. Imaging of cancer immunotherapy: response assessment methods, atypical response patterns, and immune-related adverse events, from the AJR special series on imaging of inflammation. AJR Am J Roentgenol. 2022;218(6):940\u201352.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"16216_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Fert\u00e9","year":"2014","unstructured":"Fert\u00e9 C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 2014;20(1):246\u201352.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16216_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12876-025-04596-2","volume":"26","author":"G Chen","year":"2026","unstructured":"Chen G, Wang M, Huang X, Zhang Z, Wu Y, Chen X, et al. Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma treated with TACE combined with systemic therapy. BMC Gastroenterol. 2026;26(1):119.","journal-title":"BMC Gastroenterol"},{"key":"16216_CR28","doi-asserted-by":"publisher","first-page":"104907","DOI":"10.1016\/j.critrevonc.2025.104907","volume":"214","author":"M Ebrahimnezhad","year":"2025","unstructured":"Ebrahimnezhad M, Valizadeh A, Yousefi B. Ferroptosis and immunotherapy: breaking barriers in cancer treatment resistance. Crit Rev Oncol Hematol. 2025;214:104907.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"16216_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ajh.2830310215","volume":"31","author":"WR Drobyski","year":"1989","unstructured":"Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin\u2019s lymphoma: clinical and pathogenetic considerations. Am J Hematol. 1989;31(2):138\u201341.","journal-title":"Am J Hematol"},{"issue":"1","key":"16216_CR30","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1038\/s41598-018-36184-8","volume":"8","author":"H Kim","year":"2018","unstructured":"Kim H, Kumar P, Menghi F, Noorbakhsh J, Cerveira E, Ryan M, et al. High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci Rep. 2018;8(1):17937.","journal-title":"Sci Rep"},{"key":"16216_CR31","doi-asserted-by":"publisher","first-page":"e2300260","DOI":"10.1200\/PO.23.00260","volume":"8","author":"S Simhadri","year":"2024","unstructured":"Simhadri S, Carrick JN, Murphy S, Kothari OA, Al-Hraishami H, Kulkarni A, et al. Evolution of rapid clonal dynamics and non-cross-resistance in response to alternating targeted therapy and chemotherapy in BRAF-V600E-mutant colon cancer. JCO Precis Oncol. 2024;8:e2300260.","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"16216_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong S, Wang Z, Zhang JT, Yan B, Zhang C, Gao X, et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2024;10(7):932\u201340.","journal-title":"JAMA Oncol"},{"key":"16216_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1021\/acsabm.2c00887","volume":"6","author":"A Naik","year":"2023","unstructured":"Naik A, Kumar K, Chatterjee N, Misra SK. Polyphenol-Based Nanoscale Iron Exchangers for Regulating Anticancer Chemotherapy by Modulating the Activity of Intracellular Glutathione. ACS Appl Bio Mater. 2023;6:288\u201395.","journal-title":"ACS Appl Bio Mater"},{"key":"16216_CR34","doi-asserted-by":"crossref","unstructured":"Fischer TD, Lemke-Miltner CD, Weiner GJ. Intratumoral virus-like particles containing a TLR9-agonist combined with systemic \u03b1PD-1 activate tumor-specific CD8\u2009+\u2009T cells. Cancer Res Commun. 2026.","DOI":"10.1158\/2767-9764.c.8541923"},{"issue":"13","key":"16216_CR35","doi-asserted-by":"publisher","first-page":"e141614","DOI":"10.1172\/JCI141614","volume":"131","author":"E Panagioti","year":"2021","unstructured":"Panagioti E, Kurokawa C, Viker K, Ammayappan A, Anderson SK, Sotiriou S, et al. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. J Clin Invest. 2021;131(13):e141614.","journal-title":"J Clin Invest"},{"key":"16216_CR36","doi-asserted-by":"publisher","first-page":"108286","DOI":"10.1016\/j.bioorg.2025.108286","volume":"157","author":"C Zhang","year":"2025","unstructured":"Zhang C, Peng S, Zheng Z, Chen Z, Li M, Huang N, et al. Novel bis-pocket binding aldose reductase inhibitors sensitize MCF-7\/ADR cells to doxorubicin in a dual-role manner. Bioorg Chem. 2025;157:108286.","journal-title":"Bioorg Chem"},{"key":"16216_CR37","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.7150\/thno.103636","volume":"15","author":"X Shao","year":"2025","unstructured":"Shao X, Zhao X, Wang B, Fan J, Wang J, An H. Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics. 2025;15:1689\u2013714.","journal-title":"Theranostics"},{"key":"16216_CR38","doi-asserted-by":"publisher","first-page":"104065","DOI":"10.1016\/j.critrevonc.2023.104065","volume":"188","author":"F Pasqualetti","year":"2023","unstructured":"Pasqualetti F, Barberis A, Zanotti S, Montemurro N, De Salvo GL, Soffietti R, et al. The impact of survivorship bias in glioblastoma research. Crit Rev Oncol Hematol. 2023;188:104065.","journal-title":"Crit Rev Oncol Hematol"},{"key":"16216_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/curroncol32080463","volume":"32","author":"E Uguztemur","year":"2025","unstructured":"Uguztemur E, Ozt\u00fcrk B. Impact of treatment modalities on locally advanced gastric cancer-real-world data. Curr Oncol. 2025;32:463.","journal-title":"Curr Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16216-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:03:10Z","timestamp":1786449790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16216-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16216"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16216-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was approved by the ethics committees of all three participating centers: the Ethics Committee on Clinical Trial of West China Hospital of Sichuan University (Approval No.: 2022 Clinical Trial (Western Medicine) Review No. 238), the Ethics Committee of Shandong First Medical University Affiliated Tumor Hospital (Approval No.: SDZLEC2023-203-01), and the Clinical Research Ethics Committee of the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Approval No.: 2023-003-01). All procedures complied with the Declaration of Helsinki. The written informed consent was obtained from all participants prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The consent form was signed by the patients. All authors approved the manuscript for submission.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ping Xie, Yuanfang Huang, Yan Chen and Xiaohai Tang are employees of Sichuan Enray Pharmaceutical Sciences Company, the developer of CNSI-Fe. This study was supported in part by the company. The authors declare that they have no other competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"962"}}